Effect of Reducing Palbociclib Dose on Advanced Breast Cancer Outcomes 
Palbociclib, a cyclic-dependent kinase 4/6 inhibitor, is indicated for the management of hormone-receptor positive (HR+), human epidermal growth factor receptor (HER2)-negative advanced breast cancer (BC). Dose reductions are recommended based on grade 3 or 4 adverse events, including hematological toxicity (e.g., neutropenia) and nonhematological toxicity (e.g., gastrointestinal). However, what effects such dose reductions have on outcomes is unclear. Read more.

Night-Shift Work and Breast Cancer Incidence and Mortality
Recent epidemiological evidence has associated night-shift work with adverse health effects, including increased cancer risk. While the reasons behind these negative outcomes are unclear, they may be due to alterations in the circadian clock, effects on melatonin secretion and the neuroimmune system, development of inflammation, effects on tumor suppressors, as well as the possible impact on telomere length and unhealthy habits. Read more.

Therapeutic Dose Monitoring for Tamoxifen: Guiding Therapy Using Endoxifen
Tamoxifen is the drug of choice for preventing recurrence of breast cancer (BC) in premenopausal women with hormone receptor-positive (HR+) disease. It is a prodrug that is metabolized by CYP2D6 and CYP3A4 into its active metabolites, 4-hydroxy-tamoxifen and endoxifen, the latter being the most active metabolite. Endoxifen concentrations appear to be inversely correlated with the risk of BC recurrence. Read more.